Emerging epigenetic therapeutics for myeloid leukemia: modulating demethylase activity with ascorbate

Andrew B. Das, Carlos C. Smith-Díaz and Margreet C.M. Vissers
Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand

ABSTRACT

The past decade has seen a proliferation of drugs that target epigenetic pathways. Many of these drugs were developed to treat acute myeloid leukemia, a condition in which dysregulation of the epigenetic landscape is well established. While these drugs have shown promise, critical issues persist. Specifically, patients with the same mutations respond quite differently to treatment. This is true even with highly specific drugs that are designed to target the underlying oncogenic driver mutations. Furthermore, patients who do respond may eventually develop resistance. There is now evidence that epigenetic heterogeneity contributes, in part, to these issues. Cancer cells also have a remarkable capacity to ‘rewire’ themselves at the epigenetic level in response to drug treatment, and thereby maintain expression of key oncogenes. This epigenetic plasticity is a promising new target for drug development. It is therefore important to consider combination therapy in cases in which both driver mutations and epigenetic plasticity are targeted. Using ascorbate as an example of an emerging epigenetic therapeuetic, we review the evidence for its potential use in both of these modes. We provide an overview of 2-oxoglutarate dependent dioxygenases with DNA, histone and RNA demethylase activity, focusing on those which require ascorbate as a cofactor. We also evaluate their role in the development and maintenance of acute myeloid leukemia. Using this information, we highlight situations in which the use of ascorbate to restore 2-oxoglutarate dependent dioxygenase activity could prove beneficial, in contrast to contexts in which targeted inhibition of specific enzymes might be preferred. Finally, we discuss how these insights could be incorporated into the rational design of future clinical trials.

Introduction

Acute myeloid leukemia (AML) is a cancer that arises from the stem and progenitor cells of the hematopoietic system. These abnormally differentiated, clonal cells infiltrate the bone marrow, blood and other tissues. Unless treatment is initiated early, the rapid onset of this proliferative disease is fatal. Over the past 50 years there have been remarkable improvements in the treatment of AML. Initially incurable, the 5-year survival for young patients (<60 years old) is now greater than 50%. This progress was initiated in the 1970s when the effectiveness of cytarabine and anthracyclines was discovered. Subsequently, various regimens involving combinations of the two drugs were studied to find the optimum dose, with bone marrow transplants introduced as an option in 1977. Prognosis has been even better for acute promyelocytic leukemia, a subset of AML in which the use of all-trans retinoic acid (ATRA) and arsenic trioxide has increased 5-year survival to 90%. However, for older patients, for whom intensive chemotherapy is not an option, outcomes remain bleak with a median survival of 5-11 months. Clearly, more effective treatments for AML are needed, with important clinical questions remaining, including why is there a variable response to drug therapy, and why do some patients develop resistance to therapy? When considering new treatments for AML, it is important to first evaluate our current understanding of the contributing...
variables. This will help to frame current and emerging treatment strategies for AML (Figure 1), and provide a framework for considering ascorbate as an epigenetic therapeutic.

Genetic heterogeneity in acute myeloid leukemia

As evidenced by the variable response to chemotherapy, AML is a heterogeneous disease. As the technologies available to investigate AML have developed, our understanding of where this heterogeneity lies has expanded. Morphological and cytogenetic heterogeneity have been studied for over 30 years and formed the basis for the French-American-British classification system. As genetic sequencing technologies improved, frequently mutated genes were added to classification and prognostic prediction by the World Health Organization and European LeukemiaNet. To date, next-generation sequencing technologies have shed the greatest light on heterogeneity in AML. In 2016, a landmark study that sequenced DNA samples from more than 1,540 AML patients found recurrent mutations in over 100 genes. Combining this information with cytogenetic and clinical data has shown that AML comprises at least 11 different subgroups with prognostic relevance. Therefore, substantial heterogeneity in molecular pathology underpins the apparently homogenous phenotype of patients presenting in the clinic. Single-cell sequencing has added another layer of complexity to this scenario: multiple AML clones may exist in the same patient with their relative proportions changing over time with treatment and relapse, with different co-occurring mutations contributing to different clinical outcomes.

A further insight emerging from large studies using next-generation sequencing to investigate AML is that the mutational burden is low in AML compared to other cancers, and that proteins involved in epigenetic processes are early drivers of the cancer phenotype. This information is of particular interest because the reversibility of epigenetic modifications makes these processes, and the proteins that mediate them, attractive drug targets. These data have also highlighted the potential for precision medicine, where treatments can be matched to the patient on a case-by-case basis. In the past 5 years, selective inhibitors for mutations in FLT3, IDH1 and IDH2 have gained approval from the Food and Drug Administration. There are also a growing number of clinical trials for drugs targeting epigenetic writers (DOT1L, PRMT5), readers (BRD2/3/4) and erasers (HDAC, LSD1). However, the major difficulties with targeted therapy to date, epigenetic or otherwise, are familiar adversaries: variable response to the drug, and drug resistance. At first glance this seems to be a repetition of the same issues experienced with chemotherapy. However, the nuance here is that patients with the same mutations respond quite differently to treatment. This is reported even with highly specific drugs that are designed to target the common oncogenic driver mutation. By uncovering deeper layers of heterogeneity in AML, this obstacle has provided an indication as to how it may be overcome.

Epigenetic heterogeneity, plasticity and drug resistance

We have highlighted two reasons why patients respond quite differently to treatment: inter-patient heterogeneity (genetic) and intra-patient heterogeneity (genetic/clonal). However, these factors alone do not explain why some patients eventually develop resistance to a targeted drug.

Figure 1. Levels of heterogeneity in acute myeloid leukemia and potential treatment strategies to address them. See text for further details.
The most commonly proffered reason is that the development of new mutations confers a survival advantage.\textsuperscript{13,18} This can be due to the founding clone in the primary tumor gaining mutations and evolving into the relapse clone, or a subclone of the founding clone surviving initial therapy, gaining additional mutations and expanding at relapse.\textsuperscript{19} However, there is growing evidence that non-genetic resistance also plays a role.\textsuperscript{20} Two key variables that contribute towards this outcome are epigenetic heterogeneity and epigenetic plasticity.

Epigenetic heterogeneity refers to the different epigenetic states across a population of genetically identical cells. This is a well-studied phenomenon in embryology, whereby multicellular organisms generate a vast array of cell phenotypes from a single genome. What is remarkable about normal development is the capacity of cells and organisms to produce consistent phenotypic outcomes despite being challenged by variable conditions.\textsuperscript{21,22} Waddington coined the term “canalization” to refer to this capacity of cells and used it interchangeably with the word “buffering.”\textsuperscript{23} Cancers in general and AML in particular also display buffering by producing a consistent phenotype. However, this apparent homogeneity can be unmasked by chemotherapy or targeted treatment that provides a large selection pressure. Epigenetic heterogeneity across a population of genetically identical cells means that some will be in a transcriptional state that confers resistance. Depending on the size of the fraction with resistance, this could manifest as an initial response to treatment, followed by relapse once the resistant clone has had time to regenerate the disease. Importantly, epigenetic heterogeneity has been correlated with poorer outcomes and a shorter time to relapse in AML.\textsuperscript{24}

A closely related concept is epigenetic plasticity, whereby a cell can alter its epigenetic state in a heritable manner in response to stimuli. Those cells that are able to explore the epigenetic landscape more extensively will be more likely to discover resistant states. How epigenetic heterogeneity and plasticity enable non-genetic resistance is of great interest and we recommend the review by Waddington for further discussion.\textsuperscript{25} Of interest for this review is that: (i) both genetic and non-genetic evolution contribute to resistance in AML\textsuperscript{26} and (ii) epigenetic plasticity is a new target for therapy in AML.\textsuperscript{27}

**Ascorbate as an emerging epigenetic therapeutic**

Our increased understanding of heterogeneity in AML has opened up new strategies for therapy (Figure 1). Drugs that inhibit or activate epigenetic proteins can be used to target either oncogenic driver mutations, or epigenetic plasticity. With this in mind, we review the current evidence on whether ascorbate can be used as an epigenetic therapeutic in AML. Ascorbate is synthesized from glucose in the liver or kidneys of most animals. However, humans have acquired mutations in L-gulonolactone oxidase, the terminal synthetic enzyme, and must therefore obtain ascorbate from their diet.\textsuperscript{28} Ascorbate has an essential role in human physiology through its capacity to act as an electron donor and cofactor for a wide range of enzymes including many of the 2-oxoglutarate dependent dioxygenases (OGDD).\textsuperscript{29,30} This is a large family of enzymes that includes the first enzymes known to utilize ascorbate as a cofactor, the collagen hydroxylases.\textsuperscript{31} The OGDD utilize non-heme iron (Fe\textsuperscript{2+}), 2-oxoglutarate and oxygen to catalyze a wide range of hydroxylation reactions. Many enzymes function as DNA, histone and RNA demethylases and have been shown to require ascorbate to maintain optimal activity (Table 1). This biochemistry underpins ascorbate’s link to epigenetics and has received increasing attention in multiple contexts including cancer.\textsuperscript{32,33} The findings are particularly relevant for AML because many of these demethylase enzymes are involved in the development and maintenance of AML (Table 1). Of the 20 OGDD enzymes with demethylase activity listed in Table 1, 17 play a role in the development or maintenance of AML, 15 require ascorbate as a cofactor, and 12 fall into both categories (see Table 1 for details).

**Targeting driver mutations: restoring tumor-suppressor activity**

The use of ascorbate as a drug differs from the typical scenario in which small molecules are designed to inhibit catalytic activity or interfere with protein-protein interactions. The proposed mechanism of action is that ascorbate could promote enzyme activity in cases in which decreased activity contributes to the AML phenotype. This requires residual functional enzyme to be present. We therefore propose two further criteria to select likely molecular contexts in which ascorbate might function to target oncogenic drivers. Firstly, evidence that the target demethylase functions as a tumor-suppressor in AML and secondly, that loss-of-function mutations are homozygous to ensure there is residual functional enzyme. Using the information collated in Table 1 along with previously published next-generation sequencing data from 878 AML patients accessed through cBioPortal,\textsuperscript{34} we found three demethylases that fit these criteria: $\text{TET2}$, $\text{KDM3B}$ and $\text{KDM6A}$ (Figure 2). The rest of the demethylases from Table 1 are either oncogenes in AML, are tumor suppressor genes but have increased or mixed gene expression profiles, or there is no current evidence that ascorbate acts as a cofactor. $\text{TET2}$, $\text{KDM3B}$ and $\text{KDM6A}$ are discussed here first, with the more diverse group of enzymes considered in the subsequent sections.

**Context 1. Heterozygous mutations in TET2**

Mutations in $\text{TET2}$ arise in approximately 10% of cases of AML.\textsuperscript{35-37} Similar to other mutations that affect epigenetic regulation in AML, $\text{TET2}$ mutations arise early in the development of hematopoietic malignancies.\textsuperscript{3} Mutations in $\text{TET2}$ and other epigenetic regulators are commonly found in otherwise healthy individuals with clonal hematopoiiesis, who are at risk of subsequently developing blood cancers such as AML.\textsuperscript{38-40} Mutations in $\text{TET2}$ increase hematopoietic stem cell (HSC) self-renewal and the expansion of myeloid lineage cells.\textsuperscript{41} The acquisition of subsequent mutations can lead to AML.\textsuperscript{42,43} These findings support a double-hit model in which pre-malignant HSC with $\text{TET2}$ mutations subsequently undergo further mutations leading to the development of cancer.\textsuperscript{44} $\text{TET2}$ has a fundamental role in hematopoiesis, and enables the appropriate differentiation of HSC.\textsuperscript{4} The TET enzymes are involved in active demethylation of DNA via oxidation of 5-methylcytosine to 5-hydroxymethylcytosine ($\text{5hmC}$), 5-formylcytosine, and 5-carboxylcytosine.
Table 1. Iron and 2-oxoglutarate-dependent epigenetic enzymes, their dependency on ascorbate and link to myeloid malignancies.

| Gene    | Synonyms                  | Protein                          | Substrate          | Effect of ascorbate\(\) | Role in myeloid malignancies\(\) |
|---------|---------------------------|----------------------------------|--------------------|--------------------------|----------------------------------|
| TET1    | CXXC5, KIAA1676, LCX      | Methylcytosine dioxygenase TET1  | 5mC, 5hmC and 5fC  | Increased activity      | Oncogene in AML\(^6\) and MLL-rearranged leukemia\(^7\). Reduced expression in AML\(^8\). Increased expression in MLL-rearranged leukemia\(^9\). |
| TET2    | KIAA1546, NbHa00191       | Methylcytosine dioxygenase TET2  | 5mC, 5hmC and 5fC  | Increased activity      | Tumor suppressor in AML, MDS, CMML\(^{2,3,11,12,13}\). |
| TET3    | KIAA0401                  | Methylcytosine dioxygenase TET3  | 5mC, 5hmC and 5fC  | Increased activity      | Increased expression in AML - high expression of TET3 may be a positive prognostic marker.\(^2\) Possible tumor suppressor in AML\(^3\). |
| KDM2A   | CXXC5, FBL11, FBL7, FBXL11, JHDM1A, KIAA1004 | Lysine-specific demethylase 2A | H3K36me1/me2       | Increased activity      | Tumor suppressor in MLL-rearranged leukemia - Over expression induces differentiation of MLL-AF10 transformed cells.\(^2\). |
| KDM2B   | CXXC2, FBL10, FBXL10, JHDM1B, NDY1, PCCX2 | Lysine-specific demethylase 2B | H3K36me1/me2, H3K4me5 | Increased activity      | Oncogene, required for AML cellular proliferation. Highly expressed in AML\(^4\). |
| KDM3A   | JHDM2A, JMJD1, JMJD1A, KIAA0742, TSGA | Lysine-specific demethylase 3A | H3K9me2/me1        | Increased activity      | Unknown\(^5\) |
| KDM3B   | C5orf7, JHDM2B, JMJD1B, KIAA1082 | Lysine-specific demethylase 3B | H3K9me2/me1        | Increased activity      | Tumor suppressor, transcriptionally regulates HOXA1 through retinoic acid response elements in acute myeloid leukemia.\(^6\) Also commonly deleted, or underexpressed in AML/MDS, CMML\(^5,6\). |
| KDM3C   | JHDM2C, JMJD1C, KIAA1380, TRIP8 | Lysine-specific demethylase 3C | H3K9me2/me1        | Unknown\(^7\) | Required for the survival and proliferation of some AML cell lines.\(^8\) |
| KDM4A   | JHDM3A, JMJD2, JMJD2A, KIAA0877 | Lysine-specific demethylase 4A | H3K9me3/me2        | Increased activity      | Required for MLL-AF9 translocated AML\(^9\). |
| KDM4B   | JHDM3B, JMJD2B, KIAA0876 | Lysine-specific demethylase 4B | H3K9me3/me2, H1.K26me3/me2 | Increased expression and activity in cell culture\(^{10,11}\) | Required for MLL-AF9 translocated AML\(^12\). |
| KDM4C   | GASC1, JHDM3C, JMJD2C, KIAA0760 | Lysine-specific demethylase 4C | H3K9me3/me2        | Increased activity      | Required for MLL-AF9 translocated AML\(^13\). |
| KDM5A   | JARID1A, RBBP2, RBP2      | Lysine-specific demethylase 5A | H3K4me3/me2/me1    | Increased expression     | Potentially oncogenic in AML\(^14\) NUP98/JARID1A gene fusion linked to pediatric acute megakaryoblastic leukemia\(^15\). |
| KDM5B   | JARID1B, PLU1, RBBP2H1    | Lysine-specific demethylase 5B | H3K4me3/me2/me1    | Decreased expression     | Potential tumor suppressor - MLL-AML.\(^16\) Potentially oncogenic – CML.\(^17\) AML\(^18\). |
| KDM5C   | DXS1727E, JARID1C, SMCX, XI169 | Lysine-specific demethylase 5C | H3K4me3/me2/me1    | Unknown\(^19\) | Associated with chemoresistance - pediatric AML\(^20\). |
| KDM5D   | HY, HYA, JARID1D, KIAA0234, SMCY | Lysine-specific demethylase 5D | H3K4me3/me2/me1    | Increased activity       | Unknown\(^21\) |
| KDM6A   | UTX                      | Lysine-specific demethylase 6A | H3K27me3/me2       | Increased activity       | Tumor suppressor. Low expression correlated with adverse outcome in male AML patients. Mutations in KDM6A associated with cytoreductive resistance.\(^22\) Homozygous loss |

continued on the next page
These molecules are intermediates in the pathway of DNA demethylation, and 5hmC may be an epigenetic mark with its own reader.45-48 Loss-of-function mutations in TET2 cause a significant reduction in 5hmC levels, highlighting the importance of TET2 in hydroxymethylation and epigenetic regulation more broadly.49,50 TET2, as a member of the family of OGDD, requires Fe²⁺, oxygen and 2-oxoglutarate for activity. It is now well-established that ascorbate also increases TET enzyme activity and leads to an increase in 5hmC in multiple cell culture and animal models.33,37,50,51 While still an area of active research, ascorbate has been shown to act as an electron donor to reduce inactive Fe³⁺ back to its catalytically active Fe²⁺ state, thereby increasing the Fe²⁺ necessary for TET activity.52,53,54 Furthermore, Yin et al. used fluorescence quenching to demonstrate that ascorbate uniquely interacts with the C-terminal catalytic domain of TET2, with other strong reducing chemicals not having

Figure 2. Ascorbate-dependent demethylases that function as tumor suppressors in acute myeloid leukemia. Top left panel. Relevant components of the DNA hydroxymethylation and active demethylation pathway are depicted. Top right panel. Heterozygous mutations seen in de novo acute myeloid leukemia (AML) that result in decreased TET2 activity. These mutations are mutually exclusive but collectively are found to be mutated in 30-50% of AML patients.6,59,60,122 Bottom left panel. Decreased KDM3B expression is seen in 13% of AML patients at first presentation. Bottom right panel. Heterozygous mutations in KDM3B are only seen in 1% of patients at first presentation. These data are based on next-generation sequencing of 878 AML patients accessed through cBioPortal (DNAseq = 878; RNAseq = 165). 2-OG, 2-oxoglutarate; 2-HG, 2-hydroxyglutarate.

A.B. Das et al.
a similar effect. This suggests something specific about the interaction between ascorbate and the TET enzymes, although more structural evidence is required.

A number of prominent studies have explored the specific relationship between TET activity, ascorbate, and the development of hematologic malignancies. Agathocleous et al. used Gulo−/− mice (which lack the ability to synthesize ascorbate) and showed that ascorbate deprivation resulted in a higher level of HSC relative to body mass and significantly reduced 5hmC levels in HSC, findings that are consistent with reduced TET activity. The authors then transplanted Flt3ITD/Tet2Δ/− AML cells into both Gulo−/− and control mice which resulted in accelerated development of leukemia in the Gulo−/− mice compared with the controls. Administration of ascorbate to the Flt3ITD/Tet2Δ/−/Gulo−/− mice suppressed leukemia development and prolonged survival. These results suggest that ascorbate could be beneficial in the context of leukemia with TET2 mutations. Interestingly, HSC also exhibited a 14-fold increased level of the ascorbate transporter Slc23a2 and a 6-fold higher concentration of ascorbate compared to the levels in mature immune cells, further indicating the importance of intracellular ascorbate availability to support cellular differentiation.

In another study, Cimmino et al. used RNA interference to induce and reverse the knockdown of Tet2 in mice. Tet2 knockdown caused aberrant self-renewal of HSC, which was reversed upon the restoration of TET2 activity. The restoration of TET2 activity promoted myeloid differentiation, cell death and DNA demethylation. Additionally, ascorbate administration was shown to pharmacologically mimic the effect of Tet2 restoration. An important corollary of these findings is that ascorbate depletion mimics a loss of TET2. Indeed, ascorbate deficiency was able to cooperate with Flt3ITD to promote leukemogenesis in a manner similar to Tet2 loss. A number of studies have found that patients with hematologic cancers are ascorbate deficient, and these patients are likely to have decreased TET2 activity even in the absence of TET2 mutations.

Collectively, these results indicate that the restoration of TET2 activity via ascorbate supplementation could provide an avenue for reversing disease progression in AML cases linked to heterozygous loss-of-function mutations in TET2. However, it is also important to address the issue of specificity. To what extent are the effects of ascorbate seen in the above studies mediated by mechanisms other than increased TET2 activity? Both Agathocleous et al. and Cimmino et al. found that ascorbate also had a beneficial effect when both copies of TET2 were abrogated. It is possible that ascorbate could be increasing the activity of other OGDD including histone demethylases. Agathocleous et al. did not find any evidence of increased histone methylation. Furthermore, there were no significant changes in the expression levels of Tet1-3, loss of bone collagen, depletion in carnitine or increased reactive oxygen species. Interestingly, Cimmino et al. found that knocking down Tet3 in addition to Tet2 resulted in a loss of the beneficial effect of ascorbate on both colony-forming potential as well as 5hmC. These results suggest that Tet3 was responsible for the residual effect of ascorbate in the absence of Tet2. Another mechanism proposed in the literature is that ascorbate can act as a pro-oxidant when used at high concentrations. Specifically, adding millimolar amounts of ascorbate to cell culture media can generate extracellular hydrogen peroxide via redox cycling, leading to increased cell death. Alternatively, cells can take up dehydroascorbate, an oxidation product of ascorbate, via GLUT1 which could lead to oxidative stress as the cells reduce it back to ascorbate. Agathocleous et al. did not investigate this possibility because they were not using supraphysiological concentrations of ascorbate.

Context 2. Mutations in IDH1, IDH2 and WT1 also decrease TET2 activity

In addition to heterozygous TET2 mutations, decreased TET2 activity can result from mutations in IDH1, IDH2, and WT1, particularly in the context of AML (Figure 2). Mutant isocitrate dehydrogenase (IDH) enzymes generate the oncometabolite 2-hydroxyglutarate, which acts as a competitor of TET2, in competition with its physiological substrate, 2-oxoglutarate. Wilms tumor protein 1 (WT1) is a transcription factor that recruits TET2 to DNA, enabling promoter demethylation. In both contexts, hypermethylation and decreased hydroxymethylation provide evidence of decreased TET2 activity. Data from cBioPortal and Wang et al. clearly show that mutations in the IDH1/2-TET2-WT1 pathway are mutually exclusive. Furthermore, they are collectively present in 30–50% of AML cases. Together, they constitute a distinct subtype of AML characterized by dysregulated DNA (hydroxy)methylation (Figure 2).

Ascorbate administration to mouse cells with IDH1 mutations has also been shown to reduce the rate of cellular proliferation and increase the expression of genes associated with hematopoietic differentiation. In this experiment, TET2 knockdown by short interfering RNA led to lower 5hmC increases in ascorbate-treated IDH1-mutant cells, a finding consistent with a TET2-dependent mechanism. Importantly, this study excluded the generation of hydrogen peroxide by using 2-phosphoaascorbate. This analogue of ascorbate does not redox cycle and therefore does not generate hydrogen peroxide but is converted to ascorbate during transport across the cell membrane.

In one clinical study, a patient with AML experienced a full clinical remission for 2.5 years following treatment with intravenous ascorbate. The patient had mutations in a number of genes including DNMT3a, NPM1, TET2 and WT1. The TET2 and WT1 mutations were present in separate subclones, both mutations were heterozygous, and both involved truncation of the resultant protein leading to a loss of activity. Interestingly, the WT1 clone did not emerge at relapse, suggesting that it may have been more sensitive to treatment. Together with the evidence in Context 1, these findings support the hypothesis that the clinical outcome of patients suffering from AML involving reduced TET2 activity might be improved by treatment with ascorbate.
Context 3. Decreased KDM3B expression

An unexplored context for the potential benefit of ascorbate in AML is the altered expression of KDM3B. Decreased expression of this demethylase occurs in 13% of AML cases (Figure 2). This was determined by an in silico analysis of cancer patients’ data from the COSMIC database. This study showed that, in contrast to other cancers, decreased KDM3B expression is a feature of AML. On the other hand, KDM3B acts as an oncogene in acute lymphoblastic leukemia, which highlights the importance of determining disease- and subtype-specific roles for each demethylase. Although homozygous deletions of KDM3B are found in AML, these only account for 1% of AML cases, suggesting that most cases with decreased expression could also express some functional enzyme. KDM3B (originally known as JHDM2A) specifically demethylates mono- and di-methyl lysine at position 9 on H3 (H3K9). Knockdown of this demethylase results in a build-up of H3K9me2 at specific promoters, and decreased expression of genes at these locations. Importantly, KDM3B is also a known tumor-suppressor in AML, specifically in cell lines with MLL-AF6/9 or PML-RARA translocations. Overexpression of KDM3B in these cell lines resulted in repressed colony formation, suggesting that restoration of KDM3B activity is beneficial in specific AML contexts.

Although pharmacological restoration of KDM3B has not been investigated in the context of AML, there is clear evidence that ascorbate activates KDM3B in embryonic stem cells. It was shown that ascorbate induced widespread demethylation of H3K9me2 in a KDM3A- and KDM3B-dependent manner. Given that H3K9 methylation is a repressive mark with regards to transcription, it is possible that demethylation due to KDM3B activation in the AML context reverses repression required for maintenance of AML. This hypothesis is supported by evidence that came from a screen of over 200,000 small molecules in which Xu et al. found that KA-7 was capable of upregulating KDM3B activity, and KA-7 repressed proliferation and colony-forming assays in MLL-rearranged acute leukemia with a concomitant increase in KDM3B activity (demonstrated by increased demethylation of H3K9). These data are proof-of-principle that increasing the activity of KDM3B may be beneficial for AML patients with decreased KDM3B expression. Whether this increase in activity could be achieved with ascorbate should be explored in the preclinical setting as heterozygous mutations of TET2 have been tested.

Context 4. Heterozygous KDM6A mutations, and decreased expression at relapse

Of the contexts discussed in this section, heterozygous KDM6A mutations constitute the smallest percentage of cases of de novo AML. Along with the seminal paper by Papaemmanuil et al., COŚMIC and cBioportal data show that only 1% of patients with de novo AML have a heterozygous loss-of-function mutation (Figure 2). However, KDM6A appears to be a tumor suppressor; low KDM6A expression is associated with poor survival outcomes and when KDM6A mutations arise at relapse they confer cytarabine resistance. Although cells used in follow-up cell culture experiments were either KDM6A-null or KDM6A-replete, AML patients are more likely to have heterozygous mutations than homozygous deletions. Therefore, there is likely to be functional KDM6A present, with the potential for ascorbate to increase residual enzyme activity. Interestingly, the dependence of KDM6A on ascorbate has been demonstrated both using the purified protein as well as in a hematopoietic stem cell model. Ascorbate was required for KDM6A-mediated demethylation of H3K27, which is a repressive chromatin mark. KDM6A occupies the promoters of HOX gene clusters, and demethylation of H3K27 is critical for expression of some of the HOX genes. Zhang et al. found that ascorbate was critical for the differentiation of hemogenic-endothelial cells into hematopoietic cells in a KDM6A-dependent manner. Collectively this evidence suggests that ascorbate may be beneficial for a small percentage of patients (~1%) at presentation, and potentially a much larger proportion of patients at relapse (see Context 5). As with KDM3A, this hypothesis requires further investigation at the preclinical level.

Context 5. Heterogeneous expression across patients with acute myeloid leukemia

The demethylases KDM2A, KDM2B, KDM4C, KDM5A, KDM6B, KDM7A, and KDM7B, are neither consistently upregulated nor downregulated across AML patients. Of these, KDM2A is a tumor-suppressor in the context of MLL-rearranged leukemia, in which demethylation of H3K36 leads to inactivation of genes required for maintenance of leukemia. This enzyme requires ascorbate for optimal activity; however, this finding needs to be validated in the setting of leukemia before this can be considered as a context for treatment with ascorbate.

Context 6. Inhibiting oncogenic demethylase activity

The demethylases TET1, KDM3C, KDM4A, KDM4B, KDM5B, KDM5C and FTO, are individually mutated in <1% of cases, whereas they each display increased expression in 5-7% of AML cases (Figure 5). There is evidence that TET1, KDM3C, KDM4A, KDM4B, KDM5B and FTO function as oncogenes in some AML contexts (see Table 1 for details). It is therefore interesting to consider that the inhibition of demethylases may provide clinical benefit. This possibility has been considered since the initial discovery of histone demethylases, and we sug-
gest the review by Thinnes et al. for further reading on this subject. It is interesting to note that histone deacetylase inhibitors are being investigated in clinical trials, whereas histone demethylase inhibitors have lagged behind. This is likely due to the multiple roles that histone demethylases play in AML disease progression. For example, there are conflicting reports in the literature as to whether KDM5B inhibition suppresses or promotes leukemogenesis. Clearly, further investigation is required to elucidate the specific contexts in which inhibition of these demethylases might have clinical benefit.

**Targeting epigenetic plasticity**

Cancer stem cells can evade therapy by exploring the epigenetic landscape and finding transcriptional states that confer resistance. This is a form of Lamarckian induction that is enabled by epigenetic plasticity. For example, drug treatment may result in enhancer switching to maintain the expression of key survival genes. While targeting this capacity of cancer cells is a relatively new concept, there is some evidence that KDM6A and TET2 may enable plasticity in some contexts.

**Context 7. Increasing KDM6A activity to overcome drug resistance**

Epigenetic proteins that mediate plasticity have been identified in different models of drug resistance in AML. Using overexpressed MLL-AF9 fusion protein to generate cell culture and mouse models of AML, BET inhibitor therapy was employed to create a robust model of drug resistance. Using this model, targeting the histone demethylase Lsd1(Kdm1a) overcame non-genetic, acquired resistance and re-sensitized the cells to BET inhibition. Interestingly, the CRISPR screen that identified Lsd1 as a target also showed that targeting Utx (Kdm6a) and Mll4 prevented differentiation of the resistant population. Lsd1 and Mll4 counter each other via demethylation/methylation of H3K4 at enhancers, suggesting that enhancer switching was mediating the resistant phenotype. Consistent with the emergence of new enhancers, there were also increased H3K27 acetylation and related markers at regions of increased chromatin accessibility. Importantly, KDM6A demethylates H3K27 in an ascorbate-dependent manner, which must occur prior to H3K27 acetylation. Given that knocking down Kdm6a prevented differentiation and resensitization, it is possible that ascorbate could increase Kdm6a activity and thereby augment the effect of Lsd1 inhibition in restoring sensitivity to BET inhibition. Further evidence in support of this hypothesis comes from clinical studies: when KDM6A mutations arise at relapse they confer cytarabine resistance. A follow-up study found that 45% of relapsed patients have lower KDM6A expression at relapse than at initial presentation. The same study found that KDM6A null cells were more resistant to cytarabine and daunorubicin, with repression of KDM6A restoring sensitivity to cytarabine. Determining whether treatment with ascorbate phenocopies KDM6A overexpression is a critical next step. Given that there are relatively few options for relapsed AML patients, investigating this possibility is rel-

---

**Figure 3. Context-dependent roles for demethylases in acute myeloid leukemia.** Top left panel. Heterogeneous expression of histone KDM in acute myeloid leukemia (AML) including some for which there is no clear evidence that ascorbate is required for optimal activity. Top right panel. A number of histone KDM are oncogenes and have upregulated expression in 5-7% of AML patients. Targeted inhibition of these enzymes might be beneficial. Bottom left panel. Decreased KDM6A expression is seen in 45% of AML patients at relapse and confers resistance to cytarabine. Bottom right panel. TET2 can demethylate enhancers and thereby play a role in epigenetic plasticity. Data are based on studies of 878 AML patients and were accessed through cBioPortal (DNAseq n = 878; RNAseq n = 165). 2-OH, 2-oxoglutарат.
evant for a large proportion of patients who are resistant to therapy.

**Context 8. Heterogeneous roles for TET2 at enhancers**

A number of studies have found that TET2 has the capacity to demethylate DNA at enhancers. This has been demonstrated in embryonic stem cells, hematopoietic stem cells, AML and breast cancer. In the context of AML, loss of TET2 promotes leukemogenesis via hypermethylation of enhancers. Therefore, in those cases in which heterozygous TET2 mutations are part of the natural history of AML, DNA demethylation at key enhancers would be an additional mechanism in favor of ascorbate treatment. However, the specific enhancers that TET2 binds to are cell-specific and likely to be influenced by AML subtype. It is possible that resistance to targeted treatment in TET2 wild-type AML could arise by TET2-dependent demethylation of enhancers leading to the expression of key survival genes. In this scenario direct inhibition of TET2 with small molecules might be more effective.

**Clinical trials and conclusions**

By providing an overview of the ascorbate-dependent OGD with demethylase activity, we have highlighted a range of contexts in which ascorbate could be used as an epigenetic therapeutic in AML (Contexts 1-4 and 7). Undoubtedly, the greatest weight of preclinical data supporting this is in AML with decreased TET2 activity (Contexts 1 and 2). For Contexts 3-8 much pre-clinical work remains to be done to determine whether ascorbate or, conversely, OGD inhibition may be of clinical benefit. The question remaining is, how can this be translated into clinical benefit?

It is important to note that no single-agent therapy has been effective in AML; combination therapy has been the foundation of all successful treatments. Ascorbate will therefore need to be combined with chemotherapy or other targeted therapies in randomized clinical trials in order to gauge its utility in the clinic. Thus far, only one randomized trial has reported outcomes from such a comparison: ascorbate plus decitabine prior to aclarubicin and cytarabine (A-DCAG, n=39) was compared to DCAG alone (n=34). Zhao et al. found that A-DCAG significantly increased the chance of clinical remission after first induction, as well as extending median overall survival by 6 months when compared to DCAG alone in patients over 60 years of age. This result is promising, although the findings need to be validated in a larger, randomized cohort. In addition to lack of randomization, we have noted that clinical trials looking at the benefit of ascorbate (Table 2) do not systematically evaluate the potential proposed in Contexts 1 and 2. Because most trials did not investigate TET2/IDH/WT1 mutational status, there was no way to infer the underlying mechanism of action. Future clinical trials involving ascorbate will need to stratify response by mutation status if epigenetic mechanisms of action are to be validated in patient cohorts.

Another consideration is the route of ascorbate administration. This is important because the maximum steady-state plasma concentration achievable by oral dosing is approximately 100 μM. Preclinical and clinical data suggest that oral administration may be adequate for the maintenance of TET2 function. Specifically, Agathocleous et al. found that oral supplementation was sufficient to prevent the onset of leukemia when Gulo−/− mice were transplanted with Tet2Δ/Δ;Flt3ITD/Δ leukaemic cells. Although they did not measure ShmC changes with supplementation, they did show that the ShmCmC ratio was lower in hematopoietic progenitor cells from Gulo−/− mice transplanted with Tet2Δ/Δ;Flt3ITD/Δ leukaemic cells than in Gulo−/− mice transplanted with the same cells. Furthermore, Gillberg et al. found that oral administration of ascorbate was able to increase the ShmCmC ratio in patients undergoing azacytidine treatment for myeloid neoplasms. On the other hand, Cimmino et al. used 250 μM ascorbate in cell culture, and intraperitoneal injections in experiments with mice to achieve similar results. Whether or not increasing plasma concentrations beyond the physiological maximum of 100 μM

---

Table 2. Clinical trials involving treatment with ascorbate for acute myeloid leukemia and myelodysplastic syndromes.

| Trial number       | Conditions   | Specific mutations | Drug combinations                      | Control     | Phase | Status    |
|--------------------|--------------|--------------------|----------------------------------------|-------------|-------|-----------|
| NCT0184054         | AML          | N/A                | Arsenic trioxide + ascorbate (IV)      | Single-arm  | II    | Completed |
| NCT0397173         | MDS, AML     | Heterozygous TET2  | Azacitidine + ascorbate                | Single-arm  | II    | Recruiting |
| NCT06329488        | MDS, AML     | N/A                | Manipulation of ascorbate levels       | Single-arm  | II    | Completed |
| NCT03999723        | MDS, AML, CMML | N/A                | Azacitidine + ascorbate                | Azacitidine + placebo | II    | Recruiting |
| NCT0671697         | MDS, AML     | N/A                | Decitabine, arsenic trioxide + ascorbate | Single-arm  | I     | Completed |
| NCT02877277        | MDS, AML     | TET2, DNMT3A, IDH2  | Azacitidine + ascorbate                | Azacitidine + placebo | N/A  | Completed |
| Not registered      | AML          | N/A                | Low-dose DCAG + ascorbate (IV)         | DCAG+       | N/A   | Completed |

AML, acute myeloid leukemia; N/A: not applicable; IV: intravenous; MDS: myelodysplastic syndrome; DCAG: low-dose decitabine prior to aclarubicin and cytarabine.
increases TET2 activity further and provides additional clinical benefit in humans needs to be investigated. Although achieving supraphysiological levels would require administration via an intravenous route, this should be distinguished from high-dose intravenous trials in other cancers in which plasma ascorbate concentrations can be manipulated to exceed 10 mM transiently. Interestingly, modeling of ascorbate distribution through tissues suggests that 1 mM ascorbate is sufficient for saturation of tissues distant from the blood vessel supply. Increasing the plasma concentration above this level may not have an additional impact via the epigenetic mechanisms that we have described in this paper.

Therefore, for clinicians and hematology researchers looking to investigate the use of ascorbate as an epigenetic therapeutic for AML, we recommend the following: (i) at a minimum, consider mutation, copy number, and gene expression profiling for TET2, IDH1, IDH2, WT1, KDM3B, and KDM6A and (ii) determine an appropriate dosing regimen. As part of this, whether or not supraphysiological concentrations by intravenous administration can increase O6-mercaptopurine activity beyond that achieved by oral supraphysiological administration needs to be investigated. In order to do this, levels of ascorbate and 5hmC (or histone methylation) in myeloid cells should be measured. Furthermore, the frequency of dosing and temporal relationship to standard-of-care treatment will need to be established. Where possible, deep sequencing to obtain mutational, copy number and gene expression profiling details should be carried out at diagnosis, remission and relapse to provide information on the sensitivity of subclones to treatment. This will provide ample data to determine whether epigenetic mechanisms of action for ascorbate can be validated in patient cohorts.

Disclosures

We are supported by the University of Otago, and have received funding from Canterbury Medical Research Fund, Bone Marrow Cancer Research Trust, and a NZSO Roche Translational Cancer Research Fellowship.

Contributions

ABD, CCSD and MCMV wrote the manuscript and approved the final version.

Acknowledgments

We are supported by the University of Otago, and have received funding from Canterbury Medical Research Foundation, Bone Marrow Cancer Research Trust, and a NZSO Roche Translational Cancer Research Fellowship. Birender was used in the making of figures for this publication.

References

1. Kantarjian H. Acute myeloid leukemia - major progress over four decades and glimpses into the future. Am J Hematol. 2016;91(1):131-145.
2. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1156-1152.
3. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33(4):451-458.
4. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2406.
5. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.
6. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209-2221.
7. Gerstung M, Papaemmanuil E, Martincorena I, et al. Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat Genet. 2017;49(5):532-340.
8. Potter N, Miraki-Moud F, Ermini L, et al. Single cell analysis of clonal architecture in acute myeloid leukemia. Leukemia. 2019;33(5):1115-1128.
9. Ferrando AA, López-Otín C. Clonal evolution in leukemia. Nat Med. 2017;23(4):1185-1195.
10. Kandoth C, McLellan MD, Vandin F, et al. Mutualistic landscape and significance across 12 major cancer types. Nature. 2015;520(7547):533-538.
11. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12-27.
12. Wouters BJ, Delwel R. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood. 2015;127(1):42-53.
13. Fennell KA, Bell CC, Dawson MA. Epigenetic therapies in acute myeloid leukaemia: where to from here? Blood. 2019;134(22):1891-1901.
14. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454-464.
15. Quer L, David MD, Kennedy A, et al. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nat Med. 2018;24(8):1167-1177.
16. Stein EM, DiNardo CD, Polleyea DA, et al. Enasidenib in resistant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722-731.
17. Stein EM, DiNardo CD, Fathi A, et al. Molecular remission and response patterns in patients with mutant IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019;135(7):676-687.
18. Martincorena I, Campbell PJ. Somatic mutation in cancer and normal cells. Science. 2015;349(6255):1483-1489.
19. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382):506-510.
20. Bell CC, Gilan O. Principles and mechanisms of non-genetic resistance in cancer. Br J Cancer. 2020;122(4):465-472.
21. Waddington CH. Canalization of development and the inheritance of acquired characters. Nature. 1942;150(3811):563-565.
22. Fujadas E, Feinberg AP. Regulated noise in factor for Fe- and 2-oxoglutamate dependent dioxygenases: physiological activity in tumor growth and progression. Front Oncol. 2014;4:359.
23. Vissers MCM, Das AB. Ascorbate as a co-factor for Fe- and 2-oxoglutarate dependent dioxygenases: physiological activity in tumor growth and progression. Front Oncol. 2014;4:359.
24. Li S, Garrett-Bakelman FE, Chung SS, et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nat Med. 2016;22(7):792-799.
25. F栋Y, CY, Gilan O, Lam EYN, et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature. 2015;525(7570):538-542.
26. Shlush LI, Mitchell A, Heisler L, et al. Tracking the origins of relapse in acute myeloid leukaemia to stem cells. Nature. 2017;547(7661):104-108.
27. Bell CC, Fennell KA, Chan Y-C, et al. Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. Nat Commun. 2019;10(1):2723.
28. Vissers MCM, Das AB. Potential mechanisms of action for vitamin C in cancer: reviewing the evidence. Front Physiol. 2018;9:809.
29. Kuiper C, Vissers MCM. Ascorbate as a co-factor for Fe- and 2-oxoglutarate dependent dioxygenases: physiological activity in tumor growth and progression. Front Oncol. 2014;4:359.
30. Vissers MCM, Das AB. Ascorbate as an enzyme cofactor. In: Chen Q, Vissers MCM, editors. Vitamin C: New Biochemical and Functional Insights. Boca Raton: CRC Press. p28.
31. Murad S, Grove D, Lindberg KA, Reynolds G, Sivarajah A, Pinnell SR. Regulation of collagen synthesis by ascorbic acid. Proc Natl Acad Sci U S A. 1981;78(5):2879-2882.
32. Monfort A, Wutz A. Breathing-in epigenetic change with vitamin C. EMBO Rep. 2013;14(4):357-366.
33. Young JI, Züchner S, Wang G. Regulation of the epigenome by vitamin C. Annu Rev Nutr. 2015;35(1):545-564.
34. Cerami E, Gao J, Dogrusoz U, et al. The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401-404.
35. Delhommeau E, Dupont S, Della Valle V, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2015;520(7547):533-538.
al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2010;362(27):2259-2268.

36. Ferrone CK, Blydt-Hansen M, Rau MA. Age-associated TET2 mutations: common drivers of myeloid dysfunction, cancer, and cardiovascular disease. Int J Mol Sci. 2020;21(2):626.

37. Solary E, Bernard OA, Tefferi A, Fuku F, Vainchenker W. The ten-eleven translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia. 2014;28(3):485-496.

38. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequencing. N Engl J Med. 2014;371(26):2477-2487.

39. Busque I, Patel J, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44(11):1179-1181.

40. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoiesis expansion and malignancies. Nat Med. 2014;20(12):1472-1478.

41. Cimmino L, Dolgalev I, Wang Y, et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell. 2017;170(6):1097-1105.

42. Shih AH, Jiang Y, Meydan C, et al. Mutational cooperation linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell. 2015;27(4):502-515.

43. Rasmussen KD, Jia G, Johansen JV, et al. Hematopoietic and hematopoietic stem cell transplantation exhibited depleted vitamin C status in association with febrile neutropenia. Nutrients. 2020;12(6):1856.

44. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemia ID1H and ID2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Science. 2018;359(6368):553-567.

45. Rampal R, Alkalim A, Madjoo J, et al. DNA hydroxymethylation profiling reflects that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep. 2019;4(5):1841-1856.

46. Magotra M, Sakhadiar A, Lee FJ, et al. Immunohistochemical loss of 5-hydroxymethylcytosine expression in acute myeloid leukemia: relationship to somatic gene mutations affecting epigenetic pathways. Histopathology. 2016;69(6):1055-1065.

47. Wang Y, Xiao M, Chen X, et al. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. Mol Cell. 2015;57(4):662-673.

48. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074.

49. Miragay M, Chaturvedi A, Blencky M, et al. Vitamin C-induced epigenomic remodelling in ID1H mutant acute myeloid leukaemia. Leukemia. 2018;32(1):11-20.

50. Das AB, Kakadna PM, Wójcik D, et al. Clinical remission following ascorbate treatment in acute myeloid leukemia with mutations in TET2 and WT1. Blood Cancer J. 2019;9(10):109.

51. Xu X, Nagel S, Quenemier H, et al. KDMD3 shows tumor-suppressive activity and transcriptionally regulates HOXA1 through retinoic acid response elements in acute myeloid leukemia. Leuk Lymphoma. 2018;59(9):1971-1977.

52. Kohli RM, Zeng X, Chen K, et al. Clinical remission following ascorbate treatment in a case of acute myeloid leukemia with mutations in TET2 and WT1. Blood Cancer J. 2019;9(10):109.

53. Yang T, Chen K, Sun X, et al. KDMD3 selectively represses MLL-rearranged acute Leukemia. Blood. 2018;132(Suppl 1):4682-4682.

54. Greif FA, Hartmann L, Vosberg S, et al. Evolution of cytogenetically normal acute myeloid leukemia during therapy and relapse: an exome sequencing study of 50 patients. Clin Cancer Res. 2018;24(7):1716-1726.

55. Stef SM, Hanneford A-L, Wieser S, et al. Loss of KDMD6A confers drug resistance in acute myeloid leukemia. Leukemia. 2020;34(1):50-62.

56. Wang T, Chen K, Zeng X, et al. The histone demethylases Jhd1/a/b enhance somatic cell reprogramming in vitamin C-dependent manner. Cell Stem Cell. 2011;9(6):575-587.

57. Tsukada Y, Fang J, Erdjument-Bromage H, et al. Histone demethylation by a family of JmC domain-containing proteins. Nature. 2006;449(7178):811-816.

58. Thennes CG, England KS, Kawamura A, Chowdhury R, Schrof CJ, Hopkinson RJ. Targeting histone vitamin C -mediated demethylation to plasmacytoid dendritic cells: progress, challenges, and the future. Biochim Biophys Acta. 2014;1839(12):1416-1432.

59. Tsai CT, So CWE. Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development. Oncogene. 2017;36(13):1753-1759.

60. Hong WK, Goode DL, Iwashaki M, et al. The HSF4-methyl epigenome regulates leukemia stem cell oncogenic potential. Cancer Cell. 2015;28(2):198-209.

61. Shokri G, Douti S, Fathi-Roudsari M, Knoufan F, Sanati M. Targeting histone demethylases KDMSA and KDMD5 in AML cancer cells: a comparative view. Leuk Res. 2018;66:105-111.

62. Hu MX, Huang Y, Han H, Zou Y, Huang W. JARID1B deletion induced apoptosis in Jeko-1 and HL-60 cell lines. Int J Clin Exp Pathol. 2015;8(1):171-183.

63. Shaffer SM, Dunagin MC, Torborg SR, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature. 2017;546(7658):431-438.

64. Godfrey L, Crump NT, Thome R, et al. DOT1L inhibition reverses recruitment of subsets of enhancer-dependent on H3K79 methylation. Nat Commun. 2019;10(1):2803.

65. Lavarone E, Barbieri CM, Pasini D. Dissecting the role of histone demethylation in PRC2 mediated control of cellular identity. Nat Commun. 2019;10(1):1679.

66. Rasmussen KD, Berest I, Köfler S, et al. TET2 binding to enhancers facilitates transcription factor recruitment in hematopoietic cells. Genome Res. 2019;29(4):564-575.

67. Wang L, Ozark PA, Smith EK, et al. TET2 coactivates gene expression through demethylation of enhancers. Sci Adv. 2018;4(11):eaaw6968.

68. Chua GN, Wasserman KL, Sun H, et al. Cytosine-based TET enzyme inhibitors. ACS Med Chem Lett. 2019;10(2):180-185.

69. Zhao H, Zhu H, Huang J, et al. The synergy of vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. Leuk Res. 2018;66:1-7.

70. Lykkefeldt J, Tweed-Nybørg P. The pharmacokinetics of vitamin C. Nutrients. 2019;11(10):2412.

71. Gillberg L, Örskov AD, Liu M, Hansel LBS, Jones PA, Grembaek K. Vitamin C - a new player in regulation of the cancer epigenome. Semin Cancer Biol. 2012;22(1):89-97.

72. Gillberg L, Örskov AD, Nasif A, et al. Oral...
vitamin C supplementation to patients with myeloid cancer on axacindine treatment: normalization of plasma vitamin C induces epigenetic changes. Clin Epigenetics. 2019;11(1):148.
90. Griffith M, Miller CA, Griffith OL, et al. Optimizing cancer genome sequencing and analysis. Cell Syst. 2015;10(3):210-223.
91. Hore TA, von Meyenn F, Ravichandran M, et al. Retinol and ascorb late drive erasure of epigenetic memory and enhance reprogramming to naïve pluripotency by complementary mechanisms. Proc Natl Acad Sci U S A. 2016;113(45):12202-12207.
92. Minor EA, Court BL, Young JI, Wang G. Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine. J Biol Chem. 2013;288(19):13669-13674.
93. Chen J, Guo L, Zhang L, et al. Vitamin C modulates TET1 function during somatic cell reprogramming. Nat Genet. 2013;45(12):1504-1509.
94. He X, Kim M, Kim S, et al. Vitamin C facilitates dopamine neuron differentiation in fetal midbrain through TET1- and JMJD3-dependent epigenetic control manner. Stem Cells. 2015;33(4):1320-1332.
95. Jiang X, Hu C, Ferchen K, et al. Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. Nat Commun. 2017;8(1):1299.
96. Huang H, Jiang X, Li Z, et al. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci U S A. 2015;110(29):11994-11999.
97. Zhang T, Zhao Y, Zhao Y, Zhou J. Expression and prognosis analysis of TET family in acute myeloid leukemia. Aging (Albany NY). 2020;12(6):5031-5047.
98. Shrestha R, Sakata-Yanagimoto M, Maie K, et al. Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status. Blood Adv. 2020;4(5):845-854.
99. He J, Nguyen AT, Zhang Y. KDM2b/KDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. Blood. 2011;117(14):5869-5880.
100. D’Oro A, Tan Q, Davidson AB, Yang J. Histone demethylases and their roles in cancer epigenetics. J Med Oncol Ther. 2016;1(2):34-40.
101. MacKinnon RN, Kannourakis G, Wall M, Campbell Lj. A cryptic deletion in Sqc1-2 provides further evidence for a minimally deleted region in myelodysplastic syndromes. Cancer Genet. 2011;204(4):187-194.
102. Chen M, Zhu N, Liu X, et al. JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors. Genes Dev. 2015;29(20):2123-2139.
103. Klose Rj, Yamane K, Rae Y, et al. The transcriptional repressor JHDM5A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature. 2006;442(7100):312-316.
104. Song MH, Nair VS, Oh KI. Vitamin C enhances the expression of IL17 in a JMJD2-dependent manner. MBio Rep. 2017;8(1):49-54.
105. Agger K, Miyagi S, Pedersen MT, Kooistra SM, Johansen NV, Helin K. JMJD2/Kdm4 demethylases are required for expression of Il3ra and survival of acute myeloid leukemia cells. Genes Dev. 2016;30(11):1278-1288.
106. Liu TM, Yildirim ED, Li F, et al. Ascorbate and iron are required for the specific and long-term self-renewal of human skeletal mesenchymal stromal cells. Stem Cell Rep. 2020;14(2):210-225.
107. Eid W, Abdel-Rehim W. Vitamin C promotes pluripotency of human induced pluripotent stem cells via the histone demethylase JARID1A. Biol Chem. 2016;397(11):1205-1215.
108. De Rooij JDE, Hollink IJM, Arentsen-Peters STCM, et al. NUP98/JARDIA is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia. 2013;27(12):2290-2298.
109. Yu X-X, Liu Y-H, Liu X-M, et al. Ascorbic acid induces global epigenetic reprogramming to promote meiotic maturation and developmental competence of porcine oocytes. Sci Rep. 2018;8(1):6132.
110. Xue S, Lam YM, He Z, et al. Histone lysine demethylase KDM5B maintains chronic myeloid leukemia via multiple epigenetic actions. Exp Hematol. 2020;82:53-65.
111. Zhan D, Zhang Y, Xiao P, et al. Whole exome sequencing identifies novel mutations of epigenetic regulators in chimeric-factory pediatric acute myeloid leukemia. Leukemia Res. 2018;65:20-24.
112. Lee MG, Norman J, Shilatifard A, Shiekhattar R. Physical and functional association of a trimethyl H3K4 demethylase and Ring6a/JMJD1A, a polycomb-like protein. Cell. 2007;128(5):877-887.
113. Godzeck M, Meduri E, Mazan M, et al. UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs. Nat Genet. 2018;50(6):888-894.
114. Mallaney C, Ostrander EL, Celik H, et al. Kdm6b regulates context-dependent hematopoietic stem cell self-renewal and leukemogenesis. Leukemia. 2019;33(10):2506-2521.
115. Wei Y, Chen R, Dimicoli S, et al. Global H3K4me3 genome mapping reveals alterations of innate immune signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. Leukemia 2019;33(11):2177-2186.
116. Tsukada Y, Ishitani T, Nakayama KI. KDM7 is a dual demethylase for histone H3 lysine 9 and lysine 27 and functions in brain development. J Biol Chem. 2010;285(12):9846-9854.
117. Apte M, Lu Z, Li Z, et al. The histone demethylase PHLH governs retinoic acid response in acute promyelocytic leukemia. Cancer Cell. 2016;32(3):576-589.
118. Herzen T, Girard CA, Tung Y-CI, et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nuclear acid demethylase. Science. 2007;315(5805):1469-1472.
119. Li Z, Weng H, Su R, et al. FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase. Cell Rep. 2016;15(8):1296-1308.
120. Park CH, Kimler BE, Yi SY, et al. Depletion of L-ascorbic acid alternating with its supplementation in the treatment of patients with acute myeloid leukemia or myelodysplastic syndromes. Eur J Haematol. 2009;83(2):105-118.
121. Welch JS, Rico JM, Gao F, et al. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study. Am J Hematol. 2011;86(9):796-800.
122. Metzeler KH, Herold T, Rothenberg-Thurley M, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128(5):686-698.

Emerging epigenetic therapeutics for AML